237 related articles for article (PubMed ID: 30671268)
1. Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors.
Youssef A; Kasso N; Torloni AS; Stanek M; Dragovich T; Gimbel M; Mahmoud F
Case Rep Hematol; 2018; 2018():2464619. PubMed ID: 30671268
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab-induced thrombotic thrombocytopenic purpura.
Dickey MS; Raina AJ; Gilbar PJ; Wisniowski BL; Collins JT; Karki B; Nguyen AD
J Oncol Pharm Pract; 2020 Jul; 26(5):1237-1240. PubMed ID: 31718453
[TBL] [Abstract][Full Text] [Related]
3. Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma.
Mullally WJ; Cooke FJ; Crosbie IM; Kumar S; Abernethy VE; Jordan EJ; O'Connor M; Horgan AM; Landers R; Naidoo J; Calvert PM
Front Immunol; 2022; 13():871217. PubMed ID: 35514990
[TBL] [Abstract][Full Text] [Related]
4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
5. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
[TBL] [Abstract][Full Text] [Related]
7. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
Ali AK; Watson DE
Pharmacotherapy; 2017 Nov; 37(11):1383-1390. PubMed ID: 28950039
[TBL] [Abstract][Full Text] [Related]
8. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
Thapi S; Leiter A; Galsky M; Gallagher EJ
J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP).
King J; de la Cruz J; Lutzky J
J Immunother Cancer; 2017; 5():19. PubMed ID: 28344807
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
11. Refractory thrombotic thrombocytopenic purpura related to checkpoint inhibitor immunotherapy.
Lancelot M; Miller MJ; Roback J; Stowell SR
Transfusion; 2021 Jan; 61(1):322-328. PubMed ID: 33119913
[TBL] [Abstract][Full Text] [Related]
12. Development of Bell's Palsy After Treatment With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report.
Zecchini JM; Kim S; Yum K; Friedlander P
J Immunother; 2018 Jan; 41(1):39-41. PubMed ID: 28926356
[TBL] [Abstract][Full Text] [Related]
13. Thrombotic Thrombocytopenic Purpura Induced by Immune Checkpoint Inhibitiors: A Case Report and Review of the Literature.
Ali Z; Zafar MU; Wolfe Z; Akbar F; Lash B
Cureus; 2020 Oct; 12(10):e11246. PubMed ID: 33274128
[TBL] [Abstract][Full Text] [Related]
14. Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system.
Moore DC; Elmes JB; Arnall JR; Strassels SA; Patel JN
Int Immunopharmacol; 2022 Sep; 110():109015. PubMed ID: 35803131
[TBL] [Abstract][Full Text] [Related]
15. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
16. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
17. A Rare Case of Immune-Mediated Primary Adrenal Insufficiency With Cytotoxic T-Lymphocyte Antigen-4 Inhibitor Ipilimumab in Metastatic Melanoma of Lung and Neck of Unknown Primary.
Gaballa S; Hlaing KM; Mahler N; Moursy S; Ahmed A
Cureus; 2020 Jun; 12(6):e8602. PubMed ID: 32676241
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities.
Villadolid J; Amin A
Transl Lung Cancer Res; 2015 Oct; 4(5):560-75. PubMed ID: 26629425
[TBL] [Abstract][Full Text] [Related]
19. Unique Cytologic Features of Thyroiditis Caused by Immune Checkpoint Inhibitor Therapy for Malignant Melanoma.
Angell TE; Min L; Wieczorek TJ; Hodi FS
Genes Dis; 2018 Mar; 5(1):46-48. PubMed ID: 29619406
[TBL] [Abstract][Full Text] [Related]
20. Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy.
Glutsch V; Grän F; Weber J; Gesierich A; Goebeler M; Schilling B
J Immunother Cancer; 2019 Jul; 7(1):181. PubMed ID: 31300044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
